C07C57/13

NOVEL THIAMINE-ORGANIC ACID SALT

The present disclosure relates to novel thiamine-organic acid salt, and the method of making the novel thiamine-organic acid salt.

NOVEL THIAMINE-ORGANIC ACID SALT

The present disclosure relates to novel thiamine-organic acid salt, and the method of making the novel thiamine-organic acid salt.

QUATERNARY AMMONIUM COMPOUNDS AS FUEL OR LUBRICANT ADDITIVES
20190309234 · 2019-10-10 · ·

A quaternary ammonium compound of formula (X):

##STR00001## wherein R.sup.0, R.sup.1, R.sup.2 and R.sup.3 is each individually an optionally substituted alkyl, alkenyl or aryl group and R includes an optionally substituted hydrocarbyl moiety having at least 5 carbon atoms.

QUATERNARY AMMONIUM COMPOUNDS AS FUEL OR LUBRICANT ADDITIVES
20190309234 · 2019-10-10 · ·

A quaternary ammonium compound of formula (X):

##STR00001## wherein R.sup.0, R.sup.1, R.sup.2 and R.sup.3 is each individually an optionally substituted alkyl, alkenyl or aryl group and R includes an optionally substituted hydrocarbyl moiety having at least 5 carbon atoms.

Fatty acid compound, preparation method therefor and use therefor

The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes. ##STR00001##

Fatty acid compound, preparation method therefor and use therefor

The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes. ##STR00001##

Method for thermal conversion of ketoacids and hydrotreament to hydrocarbons
10364396 · 2019-07-30 · ·

The present disclosure relates to thermal conversion of ketoacids, including methods for increasing the molecular weight of ketoacids, the method including the steps of providing in a reactor a feedstock comprising at least one ketoacid. The feedstock is then subjected to one or more C-C-coupling reaction(s) by heating the feedstock to temperature of 200-500 C. in the absence of a catalyst.

Method for thermal conversion of ketoacids and hydrotreament to hydrocarbons
10364396 · 2019-07-30 · ·

The present disclosure relates to thermal conversion of ketoacids, including methods for increasing the molecular weight of ketoacids, the method including the steps of providing in a reactor a feedstock comprising at least one ketoacid. The feedstock is then subjected to one or more C-C-coupling reaction(s) by heating the feedstock to temperature of 200-500 C. in the absence of a catalyst.

Glycosaminoglycan esters, processes for their preparation and their use in formulations for ophthalmic use
10328097 · 2019-06-25 · ·

Glycosaminoglycan esters, wherein at least part of the hydroxyl groups present on the N-acetylglucosamine residue are esterified with an apocarotenoid, their preparation, and their use in formulations for ophthalmic use are described.

METHYLENEMALONIC ACID AND INTERMEDIATES, PROCESSES FOR THEIR PREPARATION AND ENGINEERED MICROORGANISMS
20190169657 · 2019-06-06 ·

The description relates to, inter alia, recombinant microorganisms, engineered metabolic pathways, chemical catalysts, and products produced through the use of the described methods and materials. The products produced include methylenemalonic acid and intermediates, as well as their salts and esters.